Navigation Links
Vanderbilt discovery may advance colorectal cancer diagnosis and treatment
Date:7/22/2014

A Vanderbilt University-led research team has identified protein "signatures" of genetic mutations that drive colorectal cancer, the nation's second leading cause of cancer deaths after lung cancer.

The technological tour de force, described in the current issue of the journal Nature as the first integrated "proteogenomic" characterization of human cancer, "will enable new advances" in diagnosing and treating the disease, the scientists concluded.

"It's a first-of-its-kind paper. I think it's a very important advance in the field," said senior author Daniel Liebler, Ph.D., Ingram Professor of Cancer Research and director of the Jim Ayers Institute for Precancer Detection and Diagnosis at the Vanderbilt-Ingram Cancer Center.

The research team, representing Vanderbilt and six other institutions, is part of the Clinical Proteomic Tumor Analysis Consortium (CPTAC), sponsored by the National Cancer Institute of the National Institutes of Health (NIH).

Proteomics is the study of proteins. While many genetic mutations associated with cancer have been identified, it has been more difficult to analyze the structure and function of proteins that actually do cancer's "work." Until now.

The researchers used advanced mass spectrometry techniques to gather proteomic data on 95 human colorectal tumor samples characterized previously by The Cancer Genome Atlas, a federally funded project to identify genetic abnormalities in cancer.

Data analysis was led by first author Bing Zhang, Ph.D., associate professor of Biomedical Informatics. "Integrating the proteomics data with the vast amount of pre-existing genomic data is a daunting task," Zhang said, "however, it is also the key to turn the data into novel insights."

It is a basic biological principle that DNA the genetic code is "transcribed" into messenger RNA, then "translated" into proteins. Yet the researchers found that abnormalities in the genes or even the RNA of the samples did not necessarily "translate" into abnormal proteins.

Similarly, some sections of chromosomes that were "amplified" in the tumor samples did not result in amplified or increased protein levels.

Those that did, however, produced "striking effects," suggesting that proteomics might help identify and prioritize the most "impactful" genetic abnormalities that could be targets for new diagnostic tests or drug treatments, Liebler said.

The researchers also identified five subtypes of colon cancer based on their protein content, one of which was associated with poor outcomes. Proteomics thus may help identify patients who would benefit most from chemotherapy after surgery.

"Our discovery of proteomic subtypes opens the door to protein-based diagnostics that could potentially identify the bad cancers that need the aggressive therapy," Liebler said. "That's what we're really hot on going forward."

Liebler said that the support of the Ayers Institute, established in 2005 with a $10 million gift from Jim Ayers, chairman of FirstBank in Lexington, Tenn., and his wife Janet Ayers, was critical for building the infrastructure for conducting the research.

"Without the Ayers Institute, we wouldn't have been in a position to even apply for the CPTAC program, to be a part of this at all," Liebler said.

"This is exciting news that appears to have tremendous implications for cancer diagnosis and treatment," said Janet Ayers. "Jim and I extend our congratulations to Dr. Liebler and the team working with the Jim Ayers Institute for Precancer Detection and Diagnosis at the Vanderbilt-Ingram Cancer Center.

"These are the kinds of discoveries we hoped for when the institute was launched just a few years ago," she said. "To start seeing results like this so quickly is extremely rewarding."


'/>"/>
Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Vanderbilt study finds women referred for bladder cancer less often than men
2. Vanderbilt study explores genetics behind Alzheimers resiliency
3. Vanderbilt study finds physical signs of depression common among ICU survivors
4. Vanderbilt study: Ancient chemical bond may aid cancer therapy
5. Vanderbilt study finds limited resources for injured surgeons
6. AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense
7. Vanderbilt study finds lack of exercise not a factor in health disparities
8. Vanderbilt study finds maternal diet important predictor of severity for infant RSV
9. Vanderbilt study reveals clues to childhood respiratory virus
10. Vanderbilt study examines Affordable Care Acts impact on uncompensated care
11. Vanderbilt study finds diverse genetic alterations in triple-negative breast cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... ... April 30, 2017 , ... TransLiquid Cartoon is a ... X. Editors can pick and choose from a variety of liquid transitions that ... shadows using simple color swabs. Utilize on-screen controls to fully manipulate transitions through ...
(Date:4/29/2017)... Aliso Viejo, CA (PRWEB) , ... April 29, 2017 , ... ... effects. Seamlessly transition from one video to the next without having to set ... bleeding, ripping, and blasting transitions to enhance your video production. , TransDark features dynamic ...
(Date:4/28/2017)... ... 2017 , ... An April 24th article on Yahoo! Beauty discusses the case of ... of a weight loss surgery. The woman, declaring “I will not hate my body anymore!” ... her dramatic weight loss. Dr. Feiz & Associates notes that, while it often refers its ...
(Date:4/28/2017)... ... April 28, 2017 , ... Beginning in 2017, Ridgecrest Herbals will ... begins with the popular ClearLungs Extra Strength formula. To ensure that the effectiveness of ... the following ways:, , Removal of the homeopathic element , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on ... or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, ...
Breaking Medicine News(10 mins):
(Date:4/26/2017)... PROVIDENCE, N.J. , April 26, 2017 Phoenix ... announce its fifteenth year of fulfilling its mission of transforming ... industry is highly scrutinized, Phoenix,s innovative ... the healthcare community about the latest advances in science and ... Phoenix was founded in 2002 by ...
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
Breaking Medicine Technology: